Case Western Reserve University

The Cleveland Clinic Foundation

Xinning Wang

James P Basilion

Clemens Burda

Steve Shih-Lin Huang

Natalie Walker

Warren D Heston

Agata A Exner

Christopher E Hernandez

Zhenghong Lee

Dong Luo

James R Basilion

PSMA targeted conjugate compounds, pharmaceutical compositions comprising these compounds, methods for treating and detecting cancers in a subject, methods for identifying cancer cells in a sample are described herein.

PSMA targeted conjugate compounds and uses thereof

Prostate-specific membrane antigen (PSMA) targeted compounds having formula (I), nanoclusters formed thereof, pharmaceutical compositions comprising a plurality of these compounds, and methods for treating and detecting cancers in a subject are described herein.

PSMA ligand targeted compounds and uses thereof

PSMA targeted compounds, pharmaceutical compositions comprising these compounds, and methods for treating and detecting cancers in a subject are described herein.

PSMA targeted compounds and uses thereof

A PSMA-specific imaging agent comprising a compound according to formula I: 

PSMA-targeting imaging agents

A phthalocyanine compound or targeted conjugate thereof having the formula (I).

Photodynamic therapy composition

A PSMA targeted nanobubble includes a membrane that defines at least one internal void, which includes at least one gas, and at least one PSMA ligand coupled or conjugated to the membrane. The membrane includes at least one lipid and at least one nonionic triblock copolymer that is effective to control the size of the nanobubble without compromising in vitro and in vivo echogenicity of the nanobubble.

PSMA targeted nanobubbles for diagnostic and therapeutic applications

Compounds that are PSMA ligands, pharmaceutical compositions comprising these compounds, methods for treating and detecting cancers in a subject, methods for identifying cancer cells in a sample are described herein.

PSMA ligands and uses thereof

Compounds that are PSMA ligands, pharmaceutical compositions comprising these compounds, methods for treating and detecting cancers in a subject, methods for identifying cancer cells in a sample are described herein. Prostate-specific membrane antigen (PSMA) is a 120 kDa protein expressed in prostate tissues and was originally identified by reactivity with a monoclonal antibody designated 7EII-C5 (Horoszewicz et al., 1987, Anticancer Res. 7:927-935; U.S. Pat. No. 5,162,504). PSMA is characterized as a type II transmembrane protein sharing sequence identity with the transferrin receptor (Israeli et al., 1994, Cancer Res. 54:1807-1811).

A PSMA-specific imaging agent comprising a compound according to formula I: are described, wherein Sis an organic spacer group having from 5 to 30 carbons, A is an amino acid forming a portion of a negatively charged peptide oligomer, n is from 3 to 6, Sis an organic spacer group having from 5 to 15 carbons, and I is an imaging group, and pharmaceutically acceptable salts thereof. The PSMA-specific imaging agents can be used to image PSMA within a tissue region to guide the treatment of diseases such as prostate cancer.

Growing community of inventors

Cleveland, OH, United States of America

Xinning Wang